Endothelial dysfunction after androgen deprivation therapy and the possible underlying mechanisms

被引:8
|
作者
Teoh, Jeremy Yuen-Chun [1 ]
Tian, Xiao-Yu [2 ]
Wong, Christine Yim-Ping [1 ]
Lau, Chi-Wai [2 ]
Cheng, Chak-Kwong [2 ]
Tang, Victor Wai-Lun [3 ]
Chan, Ronald Cheong-Kin [4 ]
Huang, Yu [2 ]
Ng, Chi-Fai [1 ]
机构
[1] Chinese Univ Hong Kong, Dept Surg, SH Ho Urol Ctr, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Inst Vasc Med, Sch Biomed Sci, Fac Med, Hong Kong, Peoples R China
[3] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China
来源
PROSTATE | 2022年 / 82卷 / 01期
关键词
androgen deprivation therapy; cardiovascular risk; endothelial dysfunction; PROSTATE-CANCER; OXIDATIVE STRESS; HORMONE ANTAGONIST; TYROSINE NITRATION; RISK; TESTOSTERONE; PROSTACYCLIN; ORCHIECTOMY; ATHEROSCLEROSIS; INCREASES;
D O I
10.1002/pros.24244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Androgen deprivation therapy (ADT) is a key treatment modality in the management of prostate cancer (PCa), especially for patients with metastatic disease. Increasing evidences suggest that patients who received ADT have increased incidence of diabetes, myocardial infarction, stroke, and even mortality. It is important to understand the pathophysiological mechanisms on how ADT increases cardiovascular risk and induces cardiovascular events, which would provide important information for potential implementation of preventive measures. Methods Twenty-six 12-week-old male SD rats were divided into four groups for different types of ADTs including: the bilateral orchidectomy group (Orx), LHRH agonist group (leuprolide), LHRH antagonist group (degarelix), and control group. After treated with drug or adjuvant injection every 3 weeks for 24 weeks, all rats were sacrificed and total blood were collected. Aorta, renal arteries, and kidney were preserved for functional assay, immunohistochemistry, western blot, and quantitative reverse-transcription polymerase chain reaction. Results In vascular reactivity assays, aorta, intrarenal, and coronary arteries of all three ADT groups showed endothelial dysfunction. AT1R and related molecules at protein and messenger RNA (mRNA) level were tested, and AT1R pathway was shown to be activated and played a role in endothelial dysfunction. Both ACE and AT1R mRNA levels were doubled in the aorta in the leuprolide group while Orx and degarelix groups showed upregulation of AT1R in the kidney tissues. By immunohistochemistry, our result showed higher expression of AT1R in the intrarenal arteries of leuprolide and degarelix groups. The role of reactive oxygen species in endothelial dysfunction was confirmed by DHE fluorescence, nitrotyrosine overexpression, and upregulation of NOX2 in the different ADT treatment groups. Conclusion ADT causes endothelial dysfunction in male rats. GnRH receptor agonist compared to GnRH receptor antagonist, showed more impairment of endothelial function in the aorta and intrarenal arteries. Such change might be associated with upregulation and activation of AngII-AT1R-NOX2 induced oxidative stress in the vasculature. These results help to explain the different cardiovascular risks and outcomes related to different modalities of ADT treatment.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 50 条
  • [1] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
    Wadosky, Kristine M.
    Koochekpour, Shahriar
    ONCOTARGET, 2016, 7 (39) : 64447 - 64470
  • [2] Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
    Shim, Myungsun
    Bang, Woo Jin
    Oh, Cheol Young
    Lee, Yong Seong
    Cho, Jin Seon
    PROSTATE INTERNATIONAL, 2022, 10 (01) : 68 - 74
  • [3] Mechanisms underlying endothelial dysfunction in diabetes mellitus
    Hink, U
    Li, HG
    Mollnau, H
    Oelze, M
    Matheis, E
    Hartmann, M
    Skatchkov, M
    Thaiss, F
    Stahl, RAK
    Warnholtz, A
    Meinertz, T
    Griendling, K
    Harrison, DG
    Forstermann, U
    Munzel, T
    CIRCULATION RESEARCH, 2001, 88 (02) : E14 - E22
  • [4] The Confusion Surrounding Androgen Deprivation Therapy and Cognitive Dysfunction
    Pierro, Michael J.
    Kilari, Deepak
    EUROPEAN UROLOGY FOCUS, 2023, 9 (03): : 409 - 410
  • [5] Androgen deprivation therapy causes acute cardiovascular toxicity through endothelial dysfunction in a male rat model
    Teoh, J. Y. C.
    Wong, C. Y. P.
    Chan, J. H. L.
    Lau, C. W.
    Tian, X. Y.
    Huang, Y.
    Ng, C. F.
    BJU INTERNATIONAL, 2019, 123 : 9 - 9
  • [6] Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant Intense Androgen Deprivation Therapy
    Ye, Huihui
    Sowalsky, Adam G.
    Schaefer, Rachel
    Yuan, Xin
    Chen, Shao-yong
    Gerrin, Sean J.
    Montaser, Laleh
    Ma, Fen
    Voznesensky, Olga
    Cai, Changmeng
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Maly-Ellen
    Balk, Steven
    MODERN PATHOLOGY, 2016, 29 : 271A - 271A
  • [7] Diversity of Resistance Mechanisms in Prostate Cancer after Neoadjuvant Intense Androgen Deprivation Therapy
    Ye, Huihui
    Sowalsky, Adam G.
    Schaefer, Rachel
    Yuan, Xin
    Chen, Shao-Yong
    Gerrin, Sean J.
    Montaser, Laleh
    Ma, Fen
    Voznesensky, Olga
    Cai, Changmeng
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Mary-Ellen
    Balk, Steven
    LABORATORY INVESTIGATION, 2016, 96 : 271A - 271A
  • [8] Testosterone recovery after androgen deprivation therapy
    Ho, Austin Y.
    Li, Eric V.
    Bennett, Richard
    Suk-ouichai, Chalairat
    Kumar, Sai Kaushik Shankar Ramesh
    Neill, Clayton
    Li, Yutai
    Schaeffer, Edward M.
    Morgans, Alicia K.
    Patel, Hiten D.
    Ross, Ashley E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (01) : 65e1 - 65e8
  • [9] TESTOSTERONE RECOVERY AFTER ANDROGEN DEPRIVATION THERAPY
    Ho, Austin Y.
    Li, Eric, V
    Bennet, Richard
    Suk-ouichai, Chalairat
    Kumar, Sai
    Neill, Clayton
    Patel, Hiten D.
    Schaeffer, Edward M.
    Ross, Ashley E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S74 - S75
  • [10] Aging kidneys reveal underlying mechanisms of endothelial dysfunction
    Ekperikpe, Ubong S.
    Daehn, Ilse S.
    KIDNEY INTERNATIONAL, 2024, 106 (03) : 356 - 358